Osiris Therapeutics, Inc. (NASDA ...by
Osiris Therapeutics, Inc. (NASDAQ:OSIR) announced that Prochymal has received Fast Track designation from the U.S. Food and Drug Administration (FDA), expediting development of the stem cell therapy as a first-line agent fo
Fampridine-SR update from Acorda Therapeuticsby
Acorda Therapeutics Inc has added a news release to its Investor Relations website.
Title: Biogen Idec and Acorda Therapeutics Announce Collaboration Agreement to Develop and Commercialize MS Therapy Fampridine-SR in Mar